The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
FG-3019, a human monoclonal antibody to connective tissue growth factor (CTGF), with gemcitabine/erlotinib (G/E) in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).
Vincent J. Picozzi
No relevant relationships to disclose
J. Marc Pipas
No relevant relationships to disclose
Albert Koong
No relevant relationships to disclose
Amato Giaccia
Consultant or Advisory Role - FibroGen
Honoraria - FibroGen
Nathan Bahary
No relevant relationships to disclose
Smitha S. Krishnamurthi
No relevant relationships to disclose
Charles D. Lopez
No relevant relationships to disclose
Peter J. O'Dwyer
No relevant relationships to disclose
Katharina Modelska
Stock Ownership - FibroGen
Other Remuneration - FibroGen
Mairead Carney
Employment or Leadership Position - FibroGen
Stock Ownership - FibroGen
Heather Hernandez
Employment or Leadership Position - FibroGen
James Chou
Employment or Leadership Position - FibroGen
Stock Ownership - FibroGen
Tyson Lee
Employment or Leadership Position - FibroGen
Stock Ownership - FibroGen
Ming Zhong
Employment or Leadership Position - FibroGen
Stock Ownership - FibroGen
Seth Porter
Employment or Leadership Position - FibroGen
Stock Ownership - FibroGen
Tom Neff
Employment or Leadership Position - FibroGen
Stock Ownership - FibroGen
Frank Valone
Employment or Leadership Position - FibroGen
Stock Ownership - FibroGen